DBV Technologies SA
DBVTHealthcare|Biotechnology|France
$16.49
+0.41 (+2.55%)
Tangible Book
$3.53
Earnings Power
$2.43
Upcoming Data Readouts (1)
Nov 2026
Est. completion
P3Allergy
Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)
NCT07003919n=480
Awaiting Results (1)
Trials past primary completion date but still active — data readout may be imminent.
Nov 2025
P3
Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age
NCT05741476